published meta-analysis   sensitivity analysis   studies

hydroxychloroquine in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsDuke University hydroxychloroquine/azithromycine, 2020 0.50 [0.01; 19.56] 0.50[0.01; 19.56]Duke University hydroxychloroquine/azithromycine, 202010%5NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-05-03 15:22 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 657,832 - roots T: 290